Company Overview of UPM Pharmaceuticals, Inc.
UPM Pharmaceuticals, Inc. provides drug development and contract manufacturing services to pharmaceutical and biotechnology industries. Its services include formulation evaluation, such as content uniformity evaluation, dissolution testing, stability assessment, in-vitro bioequivalence determination, powder flow determination, compressibility evaluation, disintegration testing, friability testing, and tap density testing; analytical services, including dissolution testing, stability testing, purity testing, impurity identification, particle size determination, compatibility testing, solubility screening, hygroscopicity studies, methods qualification and validation, protein and peptide based ...
501 5th Street
Bristol, TN 37620
Founded in 1997
Key Executives for UPM Pharmaceuticals, Inc.
Chairman of the Board and Chief Executive Officer
President and Chief Operating Officer
Executive Director of Technical Services
Vice President of Human Resources and General Counsel
Vice President of Contracting & Drug Development Services
Compensation as of Fiscal Year 2016.
UPM Pharmaceuticals, Inc. Key Developments
UPM Pharmaceuticals Opens Solids Formulation R&D Facility
Sep 29 15
UPM Pharmaceuticals announced the opening of its newly designed and qualified Solids Formulation R&D Facility. The facility is comprised of 4,000 square ft with capabilities for a wide range of pharmaceutical formulation development, including four processing suites fitted with down flow booths, a wash room, dedicated feasibility materials storage, humidity controlled capsule shell storage, and an in process testing room. The facility contains dedicated R&D equipment and scalable to clinical processing, including wet and dry granulation, particle size reduction, encapsulation, multi-layer tableting, granules, coating, hot melt extrusion and liquid fill into hard shell capsules. Batches can be processed with as little as a few hundred grams of powder allowing clients to evaluate a broad range of processes before selecting one to scale up. Additionally this saves API that is often expensive or in limited supply.
UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets
Mar 4 15
UPM Pharmaceuticals has reached an agreement with Sprout Pharmaceuticals to manufacture Flibanserin 100 mg tablets. Sprout has submitted an NDA intending for Flibanserin to be the first drug approved to treat hypoactive sexual desire disorder (HSDD), the most common form of female sexual dysfunction. The tablets will be manufactured at UPM's 475,000 square-foot manufacturing facility in Bristol, Tennessee.
UPM Pharmaceuticals Reaches Agreement with BioPharmX, Inc. to Commercially Manufacture Solid Dose Iodine Supplement Tablets for Consumer Products Sector
Dec 10 14
UPM Pharmaceuticals reached an agreement with BioPharmX, Inc. to commercially manufacture solid dose iodine supplement tablets for the consumer products sector. The tablets will be manufactured at UPM's 475,000 square-foot manufacturing facility in Bristol, Tennessee, under a commercial supply agreement. Terms of the agreement were not disclosed.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|